Tillkännagivande • 21h
Hydrix Limited has filed a Follow-on Equity Offering in the amount of AUD 8.183065 million. Hydrix Limited has filed a Follow-on Equity Offering in the amount of AUD 8.183065 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,636,613,082
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0003
Security Features: Attached Options
Transaction Features: Rights Offering Reported Earnings • Oct 13
Full year 2025 earnings released: AU$0.014 loss per share (vs AU$0.038 loss in FY 2024) Full year 2025 results: AU$0.014 loss per share (improved from AU$0.038 loss in FY 2024). Revenue: AU$10.1m (down 4.9% from FY 2024). Net loss: AU$3.65m (loss narrowed 62% from FY 2024). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Board Change • Oct 13
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 11
Full year 2025 earnings released: AU$0.014 loss per share (vs AU$0.038 loss in FY 2024) Full year 2025 results: AU$0.014 loss per share (improved from AU$0.038 loss in FY 2024). Revenue: AU$10.1m (down 4.9% from FY 2024). Net loss: AU$3.65m (loss narrowed 62% from FY 2024). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 30
Hydrix Limited, Annual General Meeting, Nov 27, 2025 Hydrix Limited, Annual General Meeting, Nov 27, 2025. New Risk • Sep 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$581k free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-AU$6.0m). Market cap is less than US$10m (AU$4.91m market cap, or US$3.24m). Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.011 loss per share (vs AU$0.038 loss in FY 2024) Full year 2025 results: AU$0.011 loss per share (improved from AU$0.038 loss in FY 2024). Revenue: AU$10.3m (down 3.4% from FY 2024). Net loss: AU$2.92m (loss narrowed 70% from FY 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. New Risk • Jan 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 62% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.9m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-AU$3.4m). Earnings have declined by 1.3% per year over the past 5 years. Market cap is less than US$10m (AU$7.36m market cap, or US$4.61m). New Risk • Dec 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.9m free cash flow). Negative equity (-AU$3.4m). Earnings have declined by 1.3% per year over the past 5 years. Market cap is less than US$10m (AU$2.73m market cap, or US$1.73m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Reported Earnings • Oct 06
Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.002 loss in FY 2023) Full year 2024 results: AU$0.038 loss per share (further deteriorated from AU$0.002 loss in FY 2023). Revenue: AU$10.6m (down 19% from FY 2023). Net loss: AU$9.56m (loss widened AU$9.16m from FY 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 19
Hydrix Limited, Annual General Meeting, Nov 25, 2024 Hydrix Limited, Annual General Meeting, Nov 25, 2024. New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Market cap is less than US$10m (AU$4.83m market cap, or US$3.14m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change). Tillkännagivande • Sep 20
Hydrix Limited, Annual General Meeting, Nov 13, 2023 Hydrix Limited, Annual General Meeting, Nov 13, 2023, at 11:01 AUS Eastern Standard Time. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.032 loss in FY 2022) Full year 2023 results: AU$0.002 loss per share (improved from AU$0.032 loss in FY 2022). Revenue: AU$14.1m (up 35% from FY 2022). Net loss: AU$396.9k (loss narrowed 93% from FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Electronic industry in Australia. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. New Risk • Jun 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 8.2% per year over the past 5 years. Market cap is less than US$10m (AU$6.86m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022) First half 2023 results: AU$0.009 loss per share (improved from AU$0.015 loss in 1H 2022). Revenue: AU$7.23m (up 40% from 1H 2022). Net loss: AU$1.96m (loss narrowed 18% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 15
Hydrix Limited Announces TGA Response to Guardian Application Hydrix Limited has been advised by the TGA that its current application for regulatory approval to market and distribute the Angel Medical Systems Guardian in Australia is not going to be accepted. Hydrix has not yet received formal notice of its decision from the TGA. Hydrix and AngelMed's position on the Guardian: Australia is one of eight countries where Hydrix has exclusive rights to distribute the Guardian covering a total population of more than 500 million people. Hydrix has commenced commercialisation of the Guardian in approved markets, including in Singapore and Malaysia, where eight successful implants have been completed. The TGA granted Hydrix until close of business the 27th of February 2023 to consider its response. Hydrix is seeking clarification from the TGA, and during this period, will consider the matters raised and evaluate the alternate pathways and options available to seek a TGA approval. The TGA has advised that in their view, AngelMed's clinical evidence did not demonstrate that the patient benefits sufficiently outweighed the risks of an implanted device using a pacemaker lead to monitor the heart signal to detect and alarm a patient of a life threatening situation. Hydrix and AngelMed are confident in the safety and efficacy of the Guardian device, and that the benefits outweigh the risks to improve the current standard of care based on more than 3,450 patient years of safety data and 1,550 patient years of efficacy /performance data. When the US FDA approved the device, it stated in its decision that the benefits outweigh the risks, and that the device "fills an unmet medical need by providing more effective diagnosis of a life-threatening condition compared to relying on patient symptoms alone." Hydrix confirms the TGA application and information variously provided included all of the information used to gain regulatory approval in the USA (June 2021), Singapore (August 2022) and Malaysia (June 2022) where it is now being prescribed to suitable ACS patients. Tillkännagivande • Dec 07
Hydrix Limited has completed a Derivatives Offering in the amount of AUD 0.252324 million. Hydrix Limited has completed a Derivatives Offering in the amount of AUD 0.252324 million.
Security Name: Options
Security Type: Equity Option
Securities Offered: 31,563,814
Price\Range: AUD 0.005
Discount Per Security: AUD 0.00015
Security Name: Options
Security Type: Equity Option
Securities Offered: 18,900,912
Price\Range: AUD 0.005
Discount Per Security: AUD 0.00015
Transaction Features: Rights Offering; Subsequent Direct Listing Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Full year 2022 earnings released: AU$0.032 loss per share (vs AU$0.068 loss in FY 2021) Full year 2022 results: AU$0.032 loss per share (up from AU$0.068 loss in FY 2021). Revenue: AU$10.5m (up 13% from FY 2021). Net loss: AU$5.55m (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 24
Hydrix Limited, Annual General Meeting, Oct 11, 2022 Hydrix Limited, Annual General Meeting, Oct 11, 2022, at 11:00 AUS Eastern Standard Time. Tillkännagivande • Aug 15
Hydrix Limited Receives Singapore HSA Approval for Guardian Device Hydrix Limited announced that the Health Services Authority of Singapore (HSA) has approved The Guardian to be marketed and distributed in Singapore by Hydrix Medical. HSA is the Singaporean Government's body responsible for regulating the importation, manufacture, export, and supply of medical devices. In Australia, Hydrix applied to the Therapeutic Goods Administration (TGA) for approval of The Guardian in July 2021 after US FDA approval in June 2021. While TGA approval is pending, and to support market adoption in Australia, Hydrix, in conjunction with a leading cardiology group, is finalising preparations for initial implants under TGA special access arrangements. These implants will be recorded in a clinical trial registry to collate and track Australian patient data after device implant. The Guardian has been available in Singapore under special access arrangements (GN27) applied for by individual surgeons. To date, Dr. Leslie Lam, a Cardiologist practising at The Farrer Cardiac Centre in Singapore, has successfully performed eight implants commencing August 2020, including one Malaysian domiciled patient who travelled to Singapore for the implant. The value of the Guardian's continuous monitoring and alert function as an adjunct to current practices for managing cardiovascular disease is clearly demonstrated. Several of the eight implanted Singaporean patients have received alerts, including in one patient a ''see doctor" diagnostic alert, leading to proactive cardiologist intervention of emerging cardiac issues resulting in life-improving changes to their medication. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 02
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.015 loss per share (up from AU$0.039 loss in 1H 2021). Revenue: AU$5.17m (up 1.5% from 1H 2021). Net loss: AU$2.40m (loss narrowed 50% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 28
Hydrix Limited announced that it expects to receive AUD 2.828 million in funding Hydrix Limited announced a private placement of 28,280,000 common shares at an issue price of AUD 0.10 per share for gross proceeds of AUD 2,828,000 on February 28, 2022. The transaction will include participation from sophisticated investors. The company will raise funding in multiple tranches, including 22,280,000 shares in first tranche for AUD 2,228,000 which is expected to close on March 7, 2022 and to issue remaining 6,000,000 shares in its second tranche. The completion of second tranche is subjected to shareholders approval. The transaction is expected to close on July 3, 2022. Reported Earnings • Sep 01
Full year 2021 earnings released: AU$0.068 loss per share (vs AU$0.043 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: AU$9.31m (down 41% from FY 2020). Net loss: AU$9.78m (loss widened 204% from FY 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 23
Hydrix Limited Completes TGA Submission for Angelmed Guardian System Hydrix Limited announced that following the recent US FDA PMA approval for commercial release in the USA of the AngelMed Guardian System (AMSG3-E), Hydrix has submitted its application to the Australian Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG). This application, which is being managed by the Hydrix Services Regulatory Team, cites the US FDA PMA approval, together with additional information specific to Australian requirements. Subject to due process, Hydrix anticipates approval to be forthcoming in the first half of calendar year 2022. Once the device is included on the ARTG, Hydrix can then market and sell the system commercially in Australia. Hydrix also continues to work with the Medical Services Advisory Committee (MSAC) for approval for listing the procedure on the Medical Benefits Schedule (MBS), to provide a fee for the implanting physician, and Prostheses List Advisory Committee (PLAC) approval, to enable reimbursement of the AngelMed device under Private Health Insurance for policy holders. Is New 90 Day High Low • Feb 26
New 90-day low: AU$0.21 The company is down 23% from its price of AU$0.28 on 27 November 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 31% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: AU$0.24 The company is down 20% from its price of AU$0.30 on 17 September 2020. The Australian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 1.0% over the same period. Tillkännagivande • Aug 24
Hydrix Limited to Report Fiscal Year 2020 Results on Aug 26, 2020 Hydrix Limited announced that they will report fiscal year 2020 results at 6:14 AM, GMT Standard Time on Aug 26, 2020 Tillkännagivande • Jul 31
Hydrix Limited has completed a Follow-on Equity Offering in the amount of AUD 1.990557 million. Hydrix Limited has completed a Follow-on Equity Offering in the amount of AUD 1.990557 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 26,540,754
Price\Range: AUD 0.075
Transaction Features: Rights Offering Tillkännagivande • Jul 08
Hydrix Limited announced that it expects to receive AUD 1 million in funding Hydrix Limited (ASX:HYD) announced that it has entered into a binding agreement for a private placement of 13,333,334 common shares at an issue price of AUD 0.075 per share for the gross proceeds of AUD 1,000,000 on July 6, 2020. The transaction included participation from sophisticated and professional investors. The company will also issue 4,444,445 option exercisable at AUD 0.12 per share on or before July 31, 2022. For every 3 new shares subscribed, the investors will receive 1 free option to acquire a shares. The transaction is subject to shareholders approval at the general meeting expected to be prior to September 30, 2020. 